BR112017014332A2 - métodos de tratamento de doenças retinianas - Google Patents

métodos de tratamento de doenças retinianas

Info

Publication number
BR112017014332A2
BR112017014332A2 BR112017014332A BR112017014332A BR112017014332A2 BR 112017014332 A2 BR112017014332 A2 BR 112017014332A2 BR 112017014332 A BR112017014332 A BR 112017014332A BR 112017014332 A BR112017014332 A BR 112017014332A BR 112017014332 A2 BR112017014332 A2 BR 112017014332A2
Authority
BR
Brazil
Prior art keywords
individual
cells
treatment methods
disease treatment
retinal disease
Prior art date
Application number
BR112017014332A
Other languages
English (en)
Portuguese (pt)
Inventor
Eithan Reubinoff Benjamin
Sherard Irving Charles
Banin Eyal
Netzer Nir
BOHANA-KASHTAN Osnat
Original Assignee
Cell Cure Neurosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56284392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017014332(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cell Cure Neurosciences Ltd filed Critical Cell Cure Neurosciences Ltd
Publication of BR112017014332A2 publication Critical patent/BR112017014332A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00727—Apparatus for retinal reattachment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Surgery (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112017014332A 2014-12-30 2015-04-30 métodos de tratamento de doenças retinianas BR112017014332A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462097753P 2014-12-30 2014-12-30
US201562116980P 2015-02-17 2015-02-17
US201562116972P 2015-02-17 2015-02-17
PCT/IL2015/050456 WO2016108219A1 (en) 2014-12-30 2015-04-30 Methods of treating retinal diseases

Publications (1)

Publication Number Publication Date
BR112017014332A2 true BR112017014332A2 (pt) 2018-01-02

Family

ID=56284392

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017014332A BR112017014332A2 (pt) 2014-12-30 2015-04-30 métodos de tratamento de doenças retinianas

Country Status (18)

Country Link
US (2) US20180008458A1 (enExample)
EP (1) EP3240612B1 (enExample)
JP (4) JP2018501281A (enExample)
KR (2) KR102359257B1 (enExample)
CN (3) CN107427534A (enExample)
AU (3) AU2015373111B2 (enExample)
BR (1) BR112017014332A2 (enExample)
CA (2) CA2972700A1 (enExample)
DK (1) DK3240612T3 (enExample)
EA (1) EA201791518A1 (enExample)
ES (1) ES2843626T3 (enExample)
HK (1) HK1246179A1 (enExample)
IL (1) IL253244B2 (enExample)
MX (1) MX2017008818A (enExample)
PH (1) PH12017501217A1 (enExample)
SG (1) SG11201705378RA (enExample)
WO (1) WO2016108219A1 (enExample)
ZA (1) ZA201704359B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011063005A2 (en) 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
MX2017008737A (es) 2014-12-30 2018-01-25 Cell Cure Neurosciences Ltd Poblaciones de celulas rpe y metodos para generar las mismas.
US20180011092A1 (en) 2014-12-30 2018-01-11 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
EA201791518A1 (ru) * 2014-12-30 2017-10-31 Селл Кьюр Нейросайансес Лтд. Способы лечения заболеваний сетчатки
US11230696B2 (en) 2015-07-29 2022-01-25 Hadasit Medical Research Services And Development Ltd. Large scale production of retinal pigment epithelial cells
PL3331994T3 (pl) 2015-08-05 2023-01-30 Cell Cure Neurosciences Ltd. Wytwarzanie komórek nabłonka barwnikowego siatkówki
AU2016303631B2 (en) 2015-08-05 2022-07-28 Cell Cure Neurosciences Ltd. Preparation of photoreceptors for the treatment of retinal diseases
CN110913874A (zh) * 2017-03-16 2020-03-24 谱系细胞疗法公司 用于测量视网膜疾病疗法的疗效的方法
WO2019028088A1 (en) 2017-07-31 2019-02-07 Biotime, Inc. COMPOSITIONS AND METHODS FOR RESTORING OR PREVENTING LOSS OF VISION CAUSED BY TRAUMATIC DISEASE OR INJURY
SG11202005795TA (en) * 2017-12-29 2020-07-29 Cell Cure Neurosciences Ltd Retinal pigment epithelium cell compositions
AU2019256723B2 (en) 2018-04-20 2025-09-04 FUJIFILM Cellular Dynamics, Inc. Method for differentiation of ocular cells and use thereof
CN108795864B (zh) * 2018-05-24 2021-08-24 中山大学中山眼科中心 一种利用人诱导多能干细胞获得富含视锥及视杆细胞的类视网膜组织的方法
US10264436B1 (en) * 2018-05-29 2019-04-16 Link Labs, Inc. BLE networking systems and methods providing central and peripheral role reversal with independent peripheral network connectivity
WO2020047476A1 (en) * 2018-08-31 2020-03-05 University Of Florida Research Foundation, Incorporated Adeno-associated viral vectors for the treatment of best disease
WO2020229628A1 (en) * 2019-05-15 2020-11-19 Novo Nordisk A/S Methods for obtaining eye field progenitor cells from human pluripotent stem cells
JP2023528362A (ja) * 2020-05-25 2023-07-04 リネージ セル セラピューティクス インコーポレイテッド 網膜の疾患及び症状を処置するための方法及び組成物
IL301042A (en) * 2020-09-03 2023-05-01 Curebiotec Gmbh Pigment epithelium-derived factor (pedf) for use in treatment of macular degeneration or choroidal neovascularisation
EP3964227A1 (en) * 2020-09-08 2022-03-09 Curebiotec GmbH Method for the treatment of a disease using pigment epithelium-derived factor (pedf)
KR102633321B1 (ko) * 2021-05-11 2024-02-05 연세대학교 산학협력단 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물
CN115137553A (zh) * 2022-07-11 2022-10-04 上海市同济医院 一种免造孔视网膜下液排出装置
CN115212233B (zh) * 2022-08-26 2024-05-28 北京市眼科研究所 用于治疗视网膜相关疾病的组合物、试剂盒及其应用
WO2024110625A1 (en) * 2022-11-24 2024-05-30 Universität Bern Cralbp based therapeutics for retinal disorders
KR102531735B1 (ko) * 2022-12-27 2023-05-12 주식회사 셀리코 초소형 자극기 및 이의 제조방법

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
ES2530370T5 (es) 2007-04-18 2018-05-28 Hadasit Medical Research Services & Development Limited Células del epitelio pigmentario de la retina derivadas de células madre
ES2764473T3 (es) * 2007-10-12 2020-06-03 Astellas Inst For Regenerative Medicine Métodos mejorados para producir células RPE y composiciones de células RPE
KR101025880B1 (ko) * 2008-10-23 2011-03-30 공희숙 성체 줄기세포를 이용한 인슐린 분비세포로의 분화 유도방법
WO2011063005A2 (en) * 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
CA2855941A1 (en) 2011-11-14 2013-05-23 Advanced Cell Technology, Inc. Pharmaceutical preparations of human rpe cells and uses thereof
US9850463B2 (en) * 2012-02-01 2017-12-26 The Regents Of The University Of California Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation
WO2013154336A1 (ko) * 2012-04-09 2013-10-17 연세대학교 산학협력단 망막하 주사 또는 추출용 중공형 마이크로니들 및 망막하 주사기
US20150368713A1 (en) * 2013-02-01 2015-12-24 THE UNITED STATES OF AMERICAN, as represented by the Secretary, Department of Health and Human Serv METHOD FOR GENERATING RETINAL PIGMENT EPITHELIUM (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCs)
EP3080248A1 (en) * 2013-12-11 2016-10-19 Pfizer Limited Method for producing retinal pigment epithelial cells
US20180011092A1 (en) 2014-12-30 2018-01-11 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
EA201791518A1 (ru) 2014-12-30 2017-10-31 Селл Кьюр Нейросайансес Лтд. Способы лечения заболеваний сетчатки
MX2017008737A (es) 2014-12-30 2018-01-25 Cell Cure Neurosciences Ltd Poblaciones de celulas rpe y metodos para generar las mismas.
KR101982801B1 (ko) * 2015-10-28 2019-05-30 서울대학교 산학협력단 망막색소상피 분화 유도용 조성물

Also Published As

Publication number Publication date
MX2017008818A (es) 2018-03-14
AU2015373111B2 (en) 2021-06-24
IL253244A0 (en) 2017-08-31
EA201791518A1 (ru) 2017-10-31
DK3240612T3 (da) 2021-01-18
KR102359257B1 (ko) 2022-02-07
US20230028133A1 (en) 2023-01-26
AU2015373111A1 (en) 2017-07-13
CN114533761A (zh) 2022-05-27
KR20170120583A (ko) 2017-10-31
CN107427534A (zh) 2017-12-01
IL253244B2 (en) 2023-09-01
JP2022125160A (ja) 2022-08-26
HK1246179A1 (zh) 2018-09-07
JP2024023611A (ja) 2024-02-21
EP3240612B1 (en) 2020-12-23
US20180008458A1 (en) 2018-01-11
CN114469998A (zh) 2022-05-13
EP3240612A1 (en) 2017-11-08
CA3175175A1 (en) 2016-07-07
JP2020143137A (ja) 2020-09-10
CA2972700A1 (en) 2016-07-07
PH12017501217A1 (en) 2018-01-29
AU2023255009A1 (en) 2023-11-16
JP2018501281A (ja) 2018-01-18
KR20220020422A (ko) 2022-02-18
WO2016108219A1 (en) 2016-07-07
EP3240612A4 (en) 2018-06-13
IL253244B1 (en) 2023-05-01
ZA201704359B (en) 2018-08-29
SG11201705378RA (en) 2017-08-30
ES2843626T3 (es) 2021-07-19
KR102514912B1 (ko) 2023-03-27
AU2021229196A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
BR112017014332A2 (pt) métodos de tratamento de doenças retinianas
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
ZA202007149B (en) High elasticity hyaluronan compositions and methods of use thereof
MX2021002321A (es) Nuevos metodos.
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
BR112015028278A2 (pt) processo para a preparação de eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico e eritrócitos assim obtidos
BR112014026088A2 (pt) produto de tratamento de tecidos, estojo, método de fabricação de um produto de tratamento de tecidos, método de tratamento, e uso do produto de tratamento de tecidos
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
BR112015001847A8 (pt) Composições e tratamento para doenças e distúrbios nos olhos
TW201613964A (en) Improved A[beta] protofibril binding antibodies
BR112016021034A8 (pt) composição farmacêutica, uso da mesma e kit
MX393900B (es) Uso de gaboxadol en el tratamiento de tinnitus.
BR112015027269A2 (pt) terapia com bacteriófagos
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
MX2025001445A (es) Anticuerpos monoclonales anti-trkb y metodos de uso
BR112015006656A8 (pt) composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
BR112017008805A2 (pt) tratamento de córnea usando laminina
PH12017501304A1 (en) Levodopa and carbidopa intestinal gel and method of use
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
BR112015022044A2 (pt) um método de proporcionar neutroproteção ocular
MX2019013137A (es) Metodos y composiciones para tratar enfermedades oculares alergicas.
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements